drugset / Trial / NCT06389214

A Clinical Trial to Assess the Efficacy and Safety of Subjects With Dry Eye Disease

NCT06389214

Phase 3 Completed 132 enrolled Aldeyra Therapeutics, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A Randomized, Double-Masked, Vehicle-Controlled Parallel Group Clinical Trial to Assess Efficacy and Safety of 0.25% Reproxalap Ophthalmic Solution Compared to Vehicle in Subjects with Dry Eye Disease

Timeline

Start
2024-04-09
Primary completion
2024-06-11
Completion
2024-06-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Reproxalap Other / unclassified 0.25 %

Indications